Figure 5.
PeptiCRAd improves tumor growth control and induces systemic tumor-specific T cell responses in a syngeneic mouse model of B16.F10.9/K1
(A) 1 × 109 VP of VALO-mD901 or PeptiCRAd VALO-mD901-Trp2 was given intratumorally 6, 7, 8, 9, 10, 22, and 34 days post-tumor implantation. Average tumor growth curves for all treatment groups are shown. (B) Immunological analysis of tumors and tumor-draining lymph nodes of treated mice. Lymph nodes from all mice from each treatment group were pooled in order to get enough cells for the flow cytometric analysis. (C) Systemic tumor-specific T cell responses were analyzed with the ELISpot assay from the spleens of treated mice. The numbers of mice in each group were 8−10. Statistical analysis was performed with two-way ANOVA. ∗∗∗p < 0.001.